{
  "docId": "019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "docSlug": "jarvis-elliott-management-gsk-letter-july-2021",
  "documentTitle": "Elliott Management GSK Letter July 2021",
  "authorId": "elliott-management-gsk-letter-july-2021",
  "authorName": null,
  "documentKindSlug": "document",
  "documentKindLabel": "Document",
  "sourceTypeSlug": "independent_analyst",
  "sourceTypeLabel": "Independent analyst",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 14,
  "pageCount": 19,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide is a text-heavy executive summary page from a larger document.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1354-774d-98d0-be219b0f6eb3/14",
  "deckHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "deckJsonHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3.json",
  "deckAnchorHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.1,
        "y": 0.9
      },
      "kind": "other",
      "text": "12 Driven by potential approvals in NSCLC, Breast and Endometrial cancer\n13 Of the top 11 large cap pharma players",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26d74f34-9773-4fe3-bf8c-b925c016f8b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.8,
        "x": 0.1,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "GSK also has a nascent specialty business with a number of near-term growth drivers including cancer treatment Zejula, which has significant potential to build upon its current ovarian cancer indication, multiplying the size of its market opportunity by >5x.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "301979f5-a42e-4bdd-9960-0e496ba33019",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Even setting aside the early stage pipeline, the Company’s £33 billion 2031 revenue target looks highly achievable, with a Shingrix-like £3-5 billion opportunity in RSV older adult, >£1 billion for pentavalent meningitis, a potential £3-5 billion opportunity in for Cabenuva / Cabotegravir for PrEP, and an opportunity of at least £2 billion in HBV.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98cd2403-16c0-4b16-96fc-b0c7086df808",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Finally, GSK has a substantial opportunity to improve New GSK margins. With significant revenue growth, combined with operating leverage, GSK’s margins should naturally increase. Additionally, the announced £1.0 billion of “Future Ready” savings should steadily improve margins to at least 30% by 2026.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3260fbe-1925-4757-98ec-7233e1d45729",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "d7ded93f-245c-48d8-8cba-a73f5b0b47be",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}